Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $251 to $247.
Share
Why It Matters
A big bank analyst thinks Axsome stock is fairly priced right now. They lowered their target price a tiny bit, suggesting caution about big growth.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.